James Comer is Chairman of the House Oversight Committee. | https://oversight.house.gov/chairman-james-comer/
The Federal Trade Commission (FTC) has reached a settlement with Express Scripts, one of the largest pharmacy benefit managers (PBMs), and its affiliated entities. The agreement will require Express Scripts to make changes to its business practices, aiming to increase transparency, reduce insulin costs for patients, and support community pharmacies.
House Committee on Oversight and Government Reform Chairman James Comer commented on the development, stating: “Today’s deal announced by the FTC is a direct result of the House Oversight Committee’s investigation that has exposed PBMs’ anticompetitive tactics driving up the cost of prescription drug prices for Americans and jeopardizing patient care. Our investigation, which culminated in a report with our findings and recommendations, found PBMs have largely operated in the dark and abused their position as middlemen to line their own pockets by passing on costs to patients. These self-benefitting tactics raise prescription drug prices, like insulin, harm Americans who need access to life-saving medication, and undermine community pharmacies. I applaud the Trump Administration for their action to drive down prescription drug prices for Americans. The House Oversight Committee will continue to do its part to ensure Americans have access to affordable medication.”
In July 2024, the House Oversight Committee released a report detailing how CVS Caremark, Express Scripts, and OptumRx—three major PBMs—have used certain pricing strategies that increased prescription drug prices and negatively affected both patients and community pharmacies across the country. That same month, committee members held a hearing with CEOs from these companies.
Chairman Comer expanded the committee's investigation in August 2025 by requesting information about how PBMs use foreign-based group purchasing organizations (GPOs) as a means of avoiding oversight in the United States.
